1. Record Nr. UNINA9910139614103321

Titolo	Current and Future Issues in Hemophilia Care / / edited by Emerito-Carlos Rodriguez-Merchan, Leonard A. Valentino
Pubbl/distr/stampa	Hoboken, : Wiley, 2011
ISBN	1-283-20458-4 9786613204585 1-119-97940-4 1-119-97937-4
Descrizione fisica	1 online resource (190 p.)
Disciplina	600 616.1572
Soggetti	Blood Coagulation Factors Hemophilia Hemorrhagic Disorders Blood Coagulation Disorders, Inherited Biological Factors Coagulation Protein Disorders Blood Proteins Blood Coagulation Disorders Proteins Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Amino Acids, Peptides, and Proteins Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases Hemophilia A Medicine Health & Biological Sciences
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.

Nota di contenuto	Current and Future Issues in Hemophilia Care; Contents; List of Contributors; Preface; Part 1: Introduction; 1 History of Hemophilia; 2 Hemophilia Care in the Modern World; 3 Comprehensive Care Model in Hemophilia; Part 2: General Topics; 4 When Should We Switch from On-Demand to Prophylaxis Regimen?; 5 Prophylaxis in Children; 6 Prophylaxis in Adults with Hemophilia; 7 The Economics of Prophylaxis: Does Prophylaxis with Clotting Factor Represent Value for Money?; 8 The Transition of Care for the Young Adult Hemophilia Patient; 9 Perinatal Clinical Care and Molecular Diagnosis in Hemophilia 10 Managing the Mature Person with Hemophilia11 Quality of Life in Hemophilia; Part 3: Inhibitors; 12 Immunology of Inhibitor Development; 13 Epidemiology of Inhibitors; 14 Early Tolerization to Minimize Inhibitors in PUPs with Hemophilia A; 15 Prediction of Inhibitors in Severe Hemophilia; 16 Genetic Basis for Inhibitor Development; 17 Non-Genetic Risk Factors for Inhibitor Development; Part 4: Inhibitor Treatment; 18 Immune Tolerance Induction Programs; 19 Prophylaxis in Hemophilia A Patients with Inhibitors; 20 Treatment of Bleeding in FVIII Inhibitor Patients 21 Discordancy of Bypassing Therapy Part 5: Joint Health and Disease; 22 Experimental Studies on Hemarthrosis, Synovitis and Arthropathy; 23 Assessment of Joint Involvement in Hemophilia; 24 Imaging of the Hemophilic Joint; 25 Initial and Advanced Stages of Hemophilic Arthropathy, and Other Musculo-Skeletal Problems: The Role of Orthopedic Surgery; 26 Perioperative Thromboprophylaxis for Persons with Hemophilia Undergoing Orthopedic Surgery; Part 6: New Developments; 27 New Technologies for the Pharmacokinetic Improvement of Coagulation Factor Proteins 28 Current and Future Approaches to Gene Therapy in Patients with Hemophilia29 New Developments in Hemophilic Arthropathy; 30 Physiotherapy Evaluation and Intervention in the Acute Hemarthrosis: Challenging the Paradigm; 31 Laboratory Assays to Predict Response to Bypassing Agents; 32 Combination/Sequential Use of Bypassing Agents; Index
Sommario/riassunto	As haemophilia is a life-long condition, continuing supervision by a group of medical personnel is required. In many countries this is provided by comprehensive care haemophilia centres where staff of all specialities concerned with treatment- haematologists, paediatricians, nurses, physiotherapists, orthopaedic surgeons - have specialized knowledge. This new book is a definitive resource on the current aspects and issues around haemophilia. Complications of haemophilia care are well covered in chapters on inhibitors, and musculoskeletal problems, as are all the latest developments in the